Search Results - "Minenza, E."

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC by Socinski, M., Creelan, B., Horn, L., Reck, M., Paz-Ares, L., Steins, M., Felip, E., van den Heuvel, M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Geese, W.J., Bhagavatheeswaran, P., Chen, A., Carbone, D.P.

Get full text

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab by Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M. G., Fenocchio, D., Stocchi, L., Foglietta, J., Ludovini, V., Minenza, E., De Angelis, V., Crinò, L.

“…Background: In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2…”
Get full text

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer by Ramalingam, S.S, Mazières, J, Planchard, D, Stinchcombe, T.E, Dy, G.K, Antonia, S.J, Horn, L, Lena, H, Minenza, E, Mennecier, B, Otterson, G.A, Campos, L.T, Gandara, D.R, Levy, B.P, Nair, S.G, Zalcman, G, Wolf, J, Baudelet, C, Lestini, B.J, Rizvi, N.A

Get full text

Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women by Colozza, M, Califano, R, Minenza, E, Dinh, P, Azambuja, E

“…Tamoxifen, a selective estrogen receptor modulator (SERM), has been used for many decades as the "gold standard" adjuvant treatment for patients with…”
Get more information

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden by Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

“…Among patients with non–small-cell lung cancer and tumors containing at least 10 mutations per megabase, the 1-year progression-free survival rate was 43% with…”
Get full text

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer by Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

“…Although pembrolizumab has appeared to be more effective than chemotherapy in patients with lung cancer whose tumors had at least 50% PD-L1–positive cells,…”
Get full text

5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)± chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC) by Gori, S, Sidoni, A, Colozza, M, Mameli, M.G, Fenocchio, D, Minenza, E, Foglietta, J, Stocchi, L, De Angelis, V, Crinò, L

Get full text

1534P - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment by Canale, M., De Luigi, N., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L., Papi, M., Bronte, G., Crinò, L., Ulivi, P.

“…Non-small cell lung cancer (NSCLC) patients carrying epidermal growth factor receptor (EGFR) mutations are sensitive to tyrosine kinase inhibitors (TKIs);…”
Get full text

TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment by Canale, M., De Luigi, N., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L., Papi, M., Bronte, G., Crinò, L., Ulivi, P.

Get full text

1534PTP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment by Canale, M, Luigi, N De, Petracci, E, Delmonte, A, Ludovini, V, Dubini, A, Baglivo, S, Minenza, E, Chiadini, E, Landi, L, Papi, M, Bronte, G, Crinò, L, Ulivi, P

“…Abstract Background Non-small cell lung cancer (NSCLC) patients carrying epidermal growth factor receptor (EGFR) mutations are sensitive to tyrosine kinase…”
Get full text

Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC) by Zalcman, G., Rizvi, N.A., Lena, H., Wolf, J., Mazieres, J., Antonia, S.J., Minenza, E., Planchard, D., Lestini, B.J., Ramalingam, S.S.

Get full text

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer by Ramalingam, S.S., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G.A., Campos, L.T., Gandara, D.R., Levy, B.P., Nair, S.G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B.J., Rizvi, N.A.

Get full text

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response by Gori, S., Ludovini, V., Colozza, M., Pistola, L., Tofanetti, F. R., Flacco, A., Foglietta, J., Minenza, E., Stocchi, L., De Angelis, V., Crinò, L.

“…Abstract only…”
Get full text